New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
10:02 EDTRYAM, LDRH, EOX, TIF, PEGI, KW, DMND, REN, MOV, ENBL, A, SFBS, NILE, ACTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Actavis (ACT) resumed with an Overweight at JPMorgan... Agilent (A) reinstated with a Neutral at Goldman... Blue Nile (NILE) initiated with a Market Perform at Barrington... Diamond Foods (DMND) initiated with an Outperform at Credit Suisse... Emerald Oil (EOX) initiated with a Buy at Brean Capital... Enable Midstream (ENBL) initiated with a Market Perform at Wells Fargo... Kennedy Wilson (KW) initiated with a Buy at Deutsche Bank... LDR Holding (LDRH) initiated with an Outperform at RBC Capital... Movado (MOV) initiated with an Outperform at Barrington... Pattern Energy (PEGI) initiated with a Buy at KeyBanc... Rayonier Advanced Materials (RYAM) initiated with an Outperform at RBC Capital... Resolute Energy (REN) initiated with a Neutral at Global Hunter... ServisFirst (SFBS) initiated with an Outperform at Raymond James... Tiffany (TIF) initiated with a Market Perform at Barrington.
News For ACT;NILE;A;DMND;EOX;ENBL;KW;LDRH;MOV;PEGI;RYAM;REN;TIF;SFBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
March 19, 2015
10:23 EDTTIFHigh option volume stocks
Subscribe for More Information
March 18, 2015
08:50 EDTACTActavis price target raised to $373 from $286 at BMO Capital
Subscribe for More Information
08:31 EDTAAgilent names president and COO Mike McMullen as CEO
Subscribe for More Information
March 17, 2015
09:19 EDTACTActavis reinstated with a Conviction Buy at Goldman
Subscribe for More Information
09:13 EDTACTActavis says Allergan CEO not joining combined company board
Subscribe for More Information
08:59 EDTACTActavis sees combined annual pro forma revenues of over $23B in 2015
Subscribe for More Information
08:58 EDTACTActavis sees double digit accretion to adjusted EPS within first 12 months
08:58 EDTACTActavis says will 'immediately begin implementing' integration plans
Subscribe for More Information
08:57 EDTACTActavis completes acquisition of Allergan
Actavis plc (ACT) announced that it has completed the acquisition of Allergan (AGN) in a cash and equity transaction valued at approximately $70.5B. The combination creates one of the world’s top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23B anticipated in 2015. Actavis continues to expect the transaction to generate double-digit accretion to non-GAAP earnings within the first 12 months, including approximately $1.8B in operating and financial synergies to be realized within one year following the close. These synergies exclude any additional revenue or manufacturing synergies, and are in addition to the $475M of annual savings previously announced by Allergan in connection with Project Endurance. Actavis further expects to generate strong operating cash flow in excess of $8B in 2016, which would enable the company to rapidly de-lever the balance sheet.
08:56 EDTACTActavis completes Allergan acquisition valued at $70.5B
Subscribe for More Information
March 16, 2015
18:38 EDTACTAmerican Airlines to replace Allergan in S&P 500 as of 3/20 close
Subscribe for More Information
16:28 EDTSFBSServisFirst raises quarterly dividend by 20% to 6c per share
Subscribe for More Information
16:10 EDTACTActavis receives FDA approval for VIIBRYD 20mg once daily
Subscribe for More Information
14:10 EDTTIFTiffany March volatility elevated into Q3 and outlook
Tiffany March call option implied volatility is at 67, April is at 31, May is at 26, August is at 25; compared to its 26-week average of 26 according to Track Data, suggesting large near term price movement into the expected release of Q4 results on March 20.
10:22 EDTACTEuropean Commission clears Actavis' pending acquisition of Allergan
Subscribe for More Information
March 13, 2015
17:33 EDTACTS&P announces changes to S&P 100 Index
Subscribe for More Information
10:00 EDTENBLOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:49 EDTAUBS life science tools/diagnostics analyst has analyst/industry conference call
Subscribe for More Information
08:03 EDTACTActavis receives FDA approval SAPHRIS for pediatric patients
Actavis announced that the FDA has approved its supplemental new drug application for SAPHRIS as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients. SAPHRIS is the only atypical antipsychotic treatment option with a sublingual formulation. The FDA approval of SAPHRIS is based on the results of a 3-week monotherapy trial in 403 pediatric patients, of which 302 pediatric patients received SAPHRIS twice daily in doses of either 2.5 mg, 5 mg or 10 mg. SAPHRIS was shown to demonstrate improvement in Young Mania Rating Scale total score and Clinical Global Impression-Bipolar Severity of Illness overall score versus placebo in a pediatric clinical trial.
06:07 EDTENBLEnable Midstream initiated with a Sector Perform at RBC Capital
Target $20.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use